Strides Pharma Science Ltd
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 5.55Strides Pharma Science Ltd, operating in the Healthcare Services sector, shows a mixed financial performance. The company demonstrates good solvency, driven by its equity ratio. Growth is a mixed bag, with strong revenue and operating profit growth offset by declines in EPS, asset growth, and net income. While interest coverage is adequate, dividend coverage is weak. Profitability metrics present a contrasting picture, with strong gross profit and operating margins. Liquidity and efficiency ratios are generally weak, indicating potential challenges in short-term obligations and asset utilization. A crucial factor to consider is the variability in the pharmaceutical industry, impacting revenue streams and profitability.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsUndervalued
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio5.20
- Financial Ratio5.00
- Profitability Ratio7.00
- Efficiency Ratio1.67
- Coverage Ratio6.80
- Solvency Ratio5.00
- Liquidity Ratio2.00
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourBullish
- 2 HoursBullish
- 4 HoursBullish
- 1 DayBullish
- 1 WeekNeutral
- 1 MonthBullish
Health Score : 5.55Strides Pharma Science Ltd, operating in the Healthcare Services sector, shows a mixed financial performance. The company demonstrates good solvency, driven by its equity ratio. Growth is a mixed bag, with strong revenue and operating profit growth offset by declines in EPS, asset growth, and net income. While interest coverage is adequate, dividend coverage is weak. Profitability metrics present a contrasting picture, with strong gross profit and operating margins. Liquidity and efficiency ratios are generally weak, indicating potential challenges in short-term obligations and asset utilization. A crucial factor to consider is the variability in the pharmaceutical industry, impacting revenue streams and profitability.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
Overall Valuation Score
P/E RATIO (TTM)
55.77
Industry Median
24.49
Small Cap Median
22.38
P/E RATIO
18.41
P/B RATIO
3.30
Industry Median
3.93
Small Cap Median
4.71
P/S RATIO
1.98
Industry Median
2.14
Small Cap Median
2.53
Others
PEG RATIO
1.06
EV/EBITDA RATIO
9.55
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹1110.9 as on Jun 19, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Concall Report⬤3rd Feb 26
Q3 FY26 Earnings Conference Call
BULLISH SENTIMENT
Growth Score : 5.20The company demonstrates mixed growth performance. Revenue and operating profit growth are strong, indicating successful market penetration and operational improvements. However, earnings per share, asset growth, and net income growth are weak.
Revenue Growth RateExcellentOperating Profit Growth RateExcellent
Earnings Per Share (EPS) GrowthPoorAsset Growth RatePoorNet Income Growth RatePoor| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | -7.42 | 20.13 | 5.48 | 17.35 | 6.44 |
| Operating Profit Growth Rate | -124.39 | -210.69 | 264.14 | 52.08 | 15.19 |
| Earnings Per Share (EPS) Growth | -271.23 | -56.21 | -65.78 | -5174.87 | -84.52 |
| Asset Growth Rate | -0.42 | -4.99 | -12.06 | 2.24 | 16.83 |
| Net Income Growth Rate | -283.72 | -55.27 | -55.66 | -3927.66 | -84.02 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Financial Score : 5.00The financial metrics present a mixed performance. Adjusted earnings per share and book value per share are low. Cash earnings per share are moderate, while dividend per share is average. However, capital expenditures are well-managed, indicating efficient use of resources.
Adjusted Earnings Per Share (Adjusted EPS)Poor
Cash Earnings Per Share (Cash EPS)WeakBook Value Per ShareWeakDividend Per Share (DPS)AverageCapital Expenditures (CapEx)Excellent| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | -28.44 | -23.22 | 10.98 | 383.91 | 66.96 |
| Cash Earnings Per Share (Cash EPS) | -26.78 | 3.44 | 13.04 | 411.96 | 84.46 |
| Book Value Per Share | 262.11 | 245.78 | 231.09 | 277.39 | 337.72 |
| Dividend Per Share (DPS) | 0 | 1.57 | 2.53 | 3.9 | 4.83 |
| Capital Expenditures (CapEx) | 68 | 88 | 29 | 174 | 412 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
Profitability Score : 7.00The company's profitability is generally strong. Gross profit margin and operating margin are high, indicating effective cost management and pricing strategies. Return on assets is also adequate, reflecting efficient asset utilization. However, return on equity and net margin are low.
Gross Profit MarginExcellentReturn on Capital Employed (ROCE)ExcellentReturn on Equity (ROE)PoorReturn on Assets (ROA)GoodOperating MarginExcellentNet MarginPoor| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | -11.86 | -2.66 | 8.07 | 13.38 | 14.88 |
| Return on Capital Employed (ROCE) | -5 | 0 | 7 | 15 | 19 |
| Return on Equity (ROE) | -20.09 | -9.58 | -4.42 | 140.99 | 18.51 |
| Return on Assets (ROA) | -1.89 | 2.2 | 9.11 | 13.54 | 13.35 |
| Operating Margin | -4.27 | 3.93 | 13.57 | 17.59 | 19.04 |
| Net Margin | -15.44 | -5.75 | -2.42 | 78.82 | 11.83 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
Efficiency Score : 1.67The company's efficiency in utilizing its assets is generally poor. Fixed asset, inventory, and receivables turnover are low, indicating underutilization. However, days sales in inventory and receivable days are high. The capital turnover ratio is also low, suggesting that the company is not generating sufficient revenue from its capital investments.
Fixed Asset Turnover RatioPoorInventory Turnover RatioPoorReceivables Turnover RatioPoorDays Sales in Inventory RatioExcellentReceivable DaysExcellentCapital Turnover RatioPoor| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 1.31 | 1.6 | 2.09 | 2.4 | 2.04 |
| Inventory Turnover Ratio | 2.89 | 3.26 | 3.15 | 3.29 | 2.84 |
| Receivables Turnover Ratio | 2.65 | 2.94 | 3.19 | 3.89 | 3.9 |
| Days Sales in Inventory Ratio | 126.3 | 111.96 | 115.87 | 110.94 | 128.52 |
| Receivable Days | 137.74 | 124.15 | 114.42 | 93.83 | 93.59 |
| Capital Turnover Ratio | 0.9 | 1.02 | 1.34 | 1.42 | 1.31 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
Coverage Score : 6.80The company's coverage ratios present a mixed picture. Interest coverage is adequate, suggesting that the company can comfortably meet its interest obligations. However, equity dividend coverage is weak, which may impact investor confidence.
Interest Coverage RatioExcellentEquity Dividend Coverage RatioPoor| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | -2.69 | -0.03 | 0.77 | 15.76 | 4.74 |
| Equity Dividend Coverage Ratio | 100 | 12.5 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
Solvency Score : 5.00The company's solvency is strong, indicating a solid long-term financial stability. The equity ratio is high, showing a strong reliance on equity financing and minimal debt. A robust equity base provides a buffer against financial distress. This suggests a conservative financial strategy.
Debt RatioExcellentDebt to Equity RatioExcellentEquity RatioExcellentDebt To Asset RatioExcellent| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.31 | 0.39 | 0.27 | 0.2 | 0.16 |
| Debt to Equity Ratio | 0.45 | 0.64 | 0.37 | 0.25 | 0.19 |
| Equity Ratio | 0.69 | 0.61 | 0.73 | 0.8 | 0.84 |
| Debt To Asset Ratio | 0.15 | 0.21 | 0.13 | 0.11 | 0.09 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
Liquidity Score : 2.00The liquidity position is weak, indicating potential difficulties in meeting short-term obligations. The current, quick, and cash ratios are low, suggesting a limited ability to convert assets into cash quickly. This could pose challenges in managing day-to-day expenses and unexpected financial needs. Monitoring and improving these ratios is essential to ensure financial stability.
Current RatioPoorQuick RatioPoorCash RatioPoorOperating Cash Flow RatioPoor| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.07 | 1.22 | 1.2 | 1.25 | 1.27 |
| Quick Ratio | 0.74 | 0.84 | 0.81 | 0.78 | 0.76 |
| Cash Ratio | 0.05 | 0.11 | 0.07 | 0.05 | 0.07 |
| Operating Cash Flow Ratio | -0.07 | 0.01 | 0.24 | 0.25 | 0.22 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | FDC Ltd | 7.64 | 22.52 | Neutral | 346.00 | 17.56 | 281.00 |
| 2 | Supriya Lifescience Ltd | 7.46 | 35.88 | Highly Overvalued | 294.00 | 25.98 | 209.00 |
| 3 | Aarti Pharmalabs Ltd | 7.46 | 35.90 | Neutral | 369.00 | 19.44 | 175.00 |
| 4 | Innova Captab Ltd | 7.36 | 38.55 | Overvalued | 243.00 | 14.63 | 141.00 |
| 5 | Akums Drugs & Pharmaceuticals Ltd | 7.28 | 37.30 | Overvalued | 522.00 | 7.09 | 256.00 |
| 6 | Marksans Pharma Ltd | 7.24 | 28.16 | Neutral | 601.00 | 6.64 | 420.00 |
| 7 | Hikal Ltd | 7.13 | -51.71 | Neutral | 220.00 | -3.95 | -49.00 |
| 8 | RPG Life Sciences Ltd | 7.12 | 32.70 | Neutral | 147.00 | 69.64 | 115.00 |
| 9 | Shilpa Medicare Ltd | 5.94 | 44.32 | Highly Overvalued | 435.00 | 6.80 | 243.00 |
| 10 | Strides Pharma Science Ltd | 5.55 | 18.41 | Undervalued | 925.00 | 19.92 | 575.00 |
| 11 | Jeena Sikho Lifecare Ltd | 5.52 | 31.22 | Neutral | 349.00 | 17.87 | 222.00 |
| 12 | Gufic BioSciences Ltd | 5.49 | 55.51 | Neutral | 151.00 | 6.30 | 64.00 |
| 13 | Dishman Carbogen Amcis Ltd | 5.38 | 27.45 | Neutral | 566.00 | -2.45 | 97.00 |
| 14 | Aarti Drugs Ltd | 5.07 | 17.34 | Undervalued | 309.00 | 18.54 | 195.00 |
| 15 | Orchid Pharma Ltd | 4.85 | 241.74 | Neutral | 41.00 | 8.91 | 21.00 |
| 16 | Sequent Scientific Ltd | 4.61 | 293.05 | Overvalued | 162.00 | 0.63 | 32.00 |
| 17 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.97 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 18 | Zota Health Care Ltd | 3.97 | -61.25 | Neutral | 19.00 | 8.06 | -74.00 |
| 19 | Procter & Gamble Health Ltd | 3.45 | 31.71 | Neutral | 457.00 | 196.94 | 327.00 |
| 20 | Sanofi India Ltd | 3.45 | 18.59 | Neutral | 491.00 | 134.52 | 413.00 |
Balanced ManagementThe management of Strides Pharma Science demonstrates a mixed performance. While sales have generally increased, inconsistencies in profitability and low ROCE/ROE raise concerns. Promoter holding has decreased over the years. Recent improvements in compounded profit growth and a substantial increase in net profit for the year ending March 2025 are positive signs, but the preceding years show significant volatility. Overall, management effectiveness is rated as mixed due to these inconsistencies.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Compounded Sales Growth (TTM) | 13% | Indicates sustained revenue expansion. |
| Net Profit (Mar 2025) | ₹3,598 Cr. | Significant improvement in profitability. | |
| CONS | ROCE (2023) | -0% | Suggests inefficient capital utilization. |
| Promoter Holding (Mar 2025) | 28.30% | Decline in promoter confidence over time. |
Financial Performance & GrowthAverageCapital Efficiency & ReturnsWeakFinancial Health & PrudenceAverageStrategic & Operational IndicatorsAverageFinancial Performance & Growth
Strides Pharma Science demonstrates fluctuating financial performance. While sales have shown consistent growth, profit margins have been volatile. The company experienced net losses in 2022, 2023 and 2024 before recovering significantly in 2025. This inconsistency raises questions about the sustainability of its profitability. While revenue expansion is a positive sign, the instability in earnings needs consideration.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Sales Growth (%) | 48.64% | -1.28% | 4.34% | 20.13% | 9.83% | 12.69% |
| Net Profit (₹ Cr.) | 902 | 486.67 | -82 | -212 | -94 | 3,598 |
| Compounded Profit Growth (%) | N/A | N/A | N/A | N/A | N/A | N/A |
Capital Efficiency & Returns
Strides Pharma Science's capital efficiency metrics raise concerns. The Return on Capital Employed (ROCE) and Return on Equity (ROE) are relatively low. ROCE fluctuated and was negative in 2023. ROE remained below 2% for the majority of the period, indicating that shareholder funds are not generating high returns. This suggests potential inefficiencies in how the company is utilizing its capital.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| ROCE % | 59.33% | 11% | -5% | -0% | 8% | 15% |
Financial Health & Prudence
Strides Pharma Science's financial health presents a mixed picture. While the company has reduced its borrowings, it still carries a significant amount of debt. The interest coverage ratio, calculated using operating profit, has been volatile, influenced by fluctuating operating profits. The company's dividend payout has been inconsistent, with no payout in some years.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Borrowings | 1666.33 | 2813 | 2567.67 | 3030 | 2517 | 1880 |
Strategic & Operational Indicators
Strides Pharma Science's operational efficiency, as indicated by its working capital management, shows some challenges. The cash conversion cycle has been relatively high, indicating a longer time to convert investments in inventory and receivables into cash. Debtor days and inventory days have been extended, suggesting potential issues with collecting payments and managing inventory effectively.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash Conversion Cycle | 82 | 117 | 156.67 | 165 | 164 | 141 |
Balanced RiskThe risk assessment for Strides Pharma Science indicates a moderate level of concern. Segment performance volatility is observed through fluctuations in quarterly sales and profit growth. The company also has foreign exchange exposure due to its international operations. The promoter holding has decreased over the years, and while debt has been reduced, it remains a significant factor.
Segment performance volatilityAverageForeign exchange or interest rate exposureAverageAccounting quality red flagsGoodSegment performance volatility
Strides Pharma Science exhibits volatility in its segment performance. The quarterly results show significant fluctuations in both sales and profit growth. This variability indicates potential challenges in maintaining consistent financial performance across different segments or markets.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| YOY Sales Growth % | -4.67% | 36.56% | 24.34% | 8.87% | 13.90% | -1.07% | 11.41% | 16.29% | 5.79% | 16.94% | 16.76% | 14.71% | 14.08% |
| YOY Profit Growth % | 99% | 39% | 87% | -10% | -123% | 86% | 109% | 115% | 203% | 818% | 5,553% | 413% | 399% |
Foreign exchange or interest rate exposure
Strides Pharma Science's operations expose it to foreign exchange and interest rate risks. As the company operates internationally, fluctuations in exchange rates can impact its revenue and profitability. Additionally, changes in interest rates can affect the cost of its borrowings.
Accounting quality red flags
The available data does not suggest any significant accounting quality red flags for Strides Pharma Science. The financial statements appear to be consistent and transparent.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 101115.30Bullish
- SMA 201113.39Bullish
- SMA 501075.75Bullish
- EMA 101114.92Bullish
- EMA 201109.96Bullish
- EMA 501088.82Bullish
- DEMA 101116.80Bullish
- DEMA 201123.84Bearish
- DEMA 501111.22Bullish
- TEMA 101114.42Bullish
- TEMA 201118.21Bullish
- TEMA 501134.35Bearish
- MACD9.18Bearish
- ADX35.37Strong Trend
- IndicatorValueSignal
- RSI60.53Neutral
- CCI30.81Neutral
- ROC 90.22Bullish
- ROC 141.22Bullish
- ROC 251.25Bullish
- Stoch K50.54Neutral
- Stoch D53.14Neutral
- IndicatorValueSignal
- BB Upper1126.02Neutral
- BB Middle1113.39Neutral
- BB Lower1100.76Neutral
- ATR11.34Low Volatility
- IndicatorValueSignal
- MFI54.69Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 101113.54Bullish
- SMA 201105.24Bullish
- SMA 501054.07Bullish
- EMA 101111.10Bullish
- EMA 201097.59Bullish
- EMA 501080.94Bullish
- DEMA 101120.97Bearish
- DEMA 201122.38Bearish
- DEMA 501084.26Bullish
- TEMA 101115.86Bullish
- TEMA 201131.15Bearish
- TEMA 501101.00Bullish
- MACD17.91Bearish
- ADX41.57Strong Trend
- IndicatorValueSignal
- RSI62.37Neutral
- CCI80.04Neutral
- ROC 91.16Bullish
- ROC 141.38Bullish
- ROC 2512.73Bullish
- Stoch K59.18Neutral
- Stoch D64.49Neutral
- IndicatorValueSignal
- BB Upper1129.35Neutral
- BB Middle1105.24Neutral
- BB Lower1081.13Neutral
- ATR16.77Low Volatility
- IndicatorValueSignal
- MFI75.33Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 101103.35Bullish
- SMA 201055.60Bullish
- SMA 501095.68Bullish
- EMA 101097.28Bullish
- EMA 201081.98Bullish
- EMA 501079.67Bullish
- DEMA 101121.50Bearish
- DEMA 201093.03Bullish
- DEMA 501089.66Bullish
- TEMA 101130.21Bearish
- TEMA 201116.18Bullish
- TEMA 50N/AN/A
- MACD12.14Bullish
- ADX29.61Strong Trend
- IndicatorValueSignal
- RSI61.95Neutral
- CCI80.73Neutral
- ROC 93.89Bullish
- ROC 1414.49Bullish
- ROC 253.79Bullish
- Stoch K89.38Overbought
- Stoch D89.07Overbought
- IndicatorValueSignal
- BB Upper1157.89Neutral
- BB Middle1055.60Neutral
- BB Lower953.31Neutral
- ATR27.06Low Volatility
- IndicatorValueSignal
- MFI91.16Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 101049.59Bullish
- SMA 201085.46Bullish
- SMA 501074.56Bullish
- SMA 100975.70Bullish
- SMA 200931.17Bullish
- EMA 101075.57Bullish
- EMA 201077.66Bullish
- EMA 501057.27Bullish
- EMA 1001008.77Bullish
- EMA 200940.50Bullish
- DEMA 101081.24Bullish
- DEMA 201074.06Bullish
- DEMA 501109.88Bullish
- DEMA 1001090.27Bullish
- DEMA 2001062.71Bullish
- TEMA 101101.22Bullish
- TEMA 201059.83Bullish
- TEMA 501105.70Bullish
- TEMA 1001115.15Bearish
- TEMA 2001074.07Bullish
- MACD-2.21Bullish
- ADX23.37Weak Trend
- IndicatorValueSignal
- RSI56.26Neutral
- CCI34.58Neutral
- ROC 14-0.09Bearish
- ROC 25-3.11Bearish
- Stoch K72.10Neutral
- Stoch D60.59Neutral
- IndicatorValueSignal
- BB Upper1205.78Neutral
- BB Middle1085.46Neutral
- BB Lower965.14Neutral
- ATR47.17Low Volatility
- IndicatorValueSignal
- MFI44.46Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 20984.29Bullish
- SMA 50920.83Bullish
- EMA 201012.92Bullish
- EMA 50917.03Bullish
- DEMA 201091.10Bearish
- DEMA 501056.17Bearish
- TEMA 201114.93Bearish
- TEMA 501066.28Bearish
- MACD60.34Bullish
- ADX27.23Strong Trend
- IndicatorValueSignal
- RSI58.30Neutral
- CCI106.73Overbought
- ROC 1422.04Bullish
- ROC 2513.40Bullish
- Stoch K60.93Neutral
- Stoch D69.31Neutral
- IndicatorValueSignal
- BB Upper1196.37Neutral
- BB Middle984.29Neutral
- BB Lower772.21Neutral
- ATR93.51High Volatility
- IndicatorValueSignal
- MFI67.71Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 6952.54Bullish
- SMA 12915.53Bullish
- SMA 24773.49Bullish
- EMA 6981.35Bullish
- EMA 12905.72Bullish
- EMA 24774.87Bullish
- DEMA 61055.92Bullish
- DEMA 121034.98Bullish
- DEMA 24998.39Bullish
- TEMA 61078.28Bullish
- TEMA 121040.91Bullish
- TEMA 241060.63Bullish
- MACD212.95Bullish
- ADX36.00Strong Trend
- IndicatorValueSignal
- RSI72.61Overbought
- CCI151.61Overbought
- ROC 25183.15Bullish
- ROC 50632.03Bullish
- Stoch K85.66Overbought
- Stoch D88.06Overbought
- IndicatorValueSignal
- BB Upper1088.47Overbought
- BB Middle823.96Neutral
- BB Lower559.45Neutral
- ATR142.34High Volatility
- IndicatorValueSignal
- MFI68.53Neutral